MX2024012371A - Composicion inmunogenica util para la vacunacion contra el rotavirus - Google Patents
Composicion inmunogenica util para la vacunacion contra el rotavirusInfo
- Publication number
- MX2024012371A MX2024012371A MX2024012371A MX2024012371A MX2024012371A MX 2024012371 A MX2024012371 A MX 2024012371A MX 2024012371 A MX2024012371 A MX 2024012371A MX 2024012371 A MX2024012371 A MX 2024012371A MX 2024012371 A MX2024012371 A MX 2024012371A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic composition
- immunogenic
- fragment
- rotavirus
- vaccination against
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000702670 Rotavirus Species 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 2
- 206010067470 Rotavirus infection Diseases 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 241000282887 Suidae Species 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 230000002550 fecal effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108700021730 rotavirus NS35 Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12351—Methods of production or purification of viral material
- C12N2720/12352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362488P | 2022-04-05 | 2022-04-05 | |
| PCT/IB2023/053433 WO2023194913A1 (en) | 2022-04-05 | 2023-04-04 | Immunogenic composition useful for vaccination against rotavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012371A true MX2024012371A (es) | 2024-11-08 |
Family
ID=86286035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012371A MX2024012371A (es) | 2022-04-05 | 2024-10-04 | Composicion inmunogenica util para la vacunacion contra el rotavirus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240050555A1 (https=) |
| EP (1) | EP4504251A1 (https=) |
| JP (1) | JP2025511739A (https=) |
| KR (1) | KR20240170836A (https=) |
| CN (1) | CN119894528A (https=) |
| AR (1) | AR128992A1 (https=) |
| AU (1) | AU2023251268A1 (https=) |
| CA (1) | CA3255048A1 (https=) |
| CL (1) | CL2024003001A1 (https=) |
| CO (1) | CO2024013522A2 (https=) |
| MX (1) | MX2024012371A (https=) |
| TW (1) | TW202404629A (https=) |
| WO (1) | WO2023194913A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025183704A1 (en) * | 2024-03-01 | 2025-09-04 | Vst Llc Dba Medgene | Rotavirus vaccines |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| EP0386185A1 (fr) | 1988-07-29 | 1990-09-12 | IntraCel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
| CA2489769A1 (en) | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| EP0620277A1 (en) | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
| FR2711670B1 (fr) | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| ATE298370T1 (de) | 1994-04-29 | 2005-07-15 | Baxter Healthcare Sa | Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen |
| EP0871755A1 (en) | 1995-03-23 | 1998-10-21 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
| EP0979101B1 (en) | 1996-07-03 | 2010-10-27 | Merial, Inc. | Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| US6187319B1 (en) * | 1998-06-01 | 2001-02-13 | University Of Massachusetts | Cross-protective rotavirus vaccine |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| US8675566B2 (en) | 2009-09-17 | 2014-03-18 | Digifonica (International) Limited | Uninterrupted transmission of internet protocol transmissions during endpoint changes |
| WO2017008049A1 (en) * | 2015-07-08 | 2017-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| CA3195910A1 (en) * | 2020-10-05 | 2022-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Fusion protein useful for vaccination against rotavirus |
-
2023
- 2023-04-04 WO PCT/IB2023/053433 patent/WO2023194913A1/en not_active Ceased
- 2023-04-04 CA CA3255048A patent/CA3255048A1/en active Pending
- 2023-04-04 US US18/295,675 patent/US20240050555A1/en active Pending
- 2023-04-04 JP JP2024559187A patent/JP2025511739A/ja active Pending
- 2023-04-04 AU AU2023251268A patent/AU2023251268A1/en active Pending
- 2023-04-04 AR ARP230100839A patent/AR128992A1/es unknown
- 2023-04-04 KR KR1020247036936A patent/KR20240170836A/ko active Pending
- 2023-04-04 CN CN202380032319.XA patent/CN119894528A/zh active Pending
- 2023-04-04 EP EP23720982.0A patent/EP4504251A1/en active Pending
- 2023-04-06 TW TW112112876A patent/TW202404629A/zh unknown
-
2024
- 2024-10-04 CL CL2024003001A patent/CL2024003001A1/es unknown
- 2024-10-04 MX MX2024012371A patent/MX2024012371A/es unknown
- 2024-10-04 CO CONC2024/0013522A patent/CO2024013522A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023194913A1 (en) | 2023-10-12 |
| CN119894528A (zh) | 2025-04-25 |
| WO2023194913A8 (en) | 2024-01-25 |
| US20240050555A1 (en) | 2024-02-15 |
| CL2024003001A1 (es) | 2025-04-04 |
| KR20240170836A (ko) | 2024-12-04 |
| EP4504251A1 (en) | 2025-02-12 |
| CO2024013522A2 (es) | 2024-10-31 |
| AU2023251268A1 (en) | 2024-11-14 |
| CA3255048A1 (en) | 2023-10-12 |
| AR128992A1 (es) | 2024-07-03 |
| JP2025511739A (ja) | 2025-04-16 |
| TW202404629A (zh) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023003544A2 (es) | Proteína de fusión útil para la vacunación contra el rotavirus | |
| MX2024012371A (es) | Composicion inmunogenica util para la vacunacion contra el rotavirus | |
| ES2602971T3 (es) | Composición de anticuerpo modificado | |
| ES2600879T3 (es) | Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas | |
| AR120563A1 (es) | Receptores de antígeno quimérico cd19 y cd22 y sus usos | |
| PE20220283A1 (es) | Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| PE20061398A1 (es) | Vacuna de toxoide de c. perfringens alfa | |
| MX2019005137A (es) | Vacuna contra parvovirus porcino. | |
| AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| MX385679B (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| MX370356B (es) | Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria. | |
| JP2014000092A5 (https=) | ||
| AR075047A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit. | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| AR095482A1 (es) | Virus del síndrome reproductivo y respiratorio porcino, composiciones, vacuna y métodos de uso | |
| MX2021012695A (es) | Vacuna de subunidad del virus de la fiebre porcina clasica (csfv). | |
| AR106792A1 (es) | Proteínas de fusión de e2 y fmdv y sus usos | |
| AR039460A1 (es) | Factores camp quimericos | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| BR112019008720A2 (pt) | polinucleotídeo isolado, polinucleotídeo de cdna, polinucleotídeo infeccioso, composição, composição farmacêutica, vetor de pestivírus porcino, pestivírus quimérico, vacina para animais, kit, métodos para proteger um leitão contra uma doença associada com pestivírus, detectar pestivírus, detectar antígeno de pestivírus, preparar uma vacina e controlar uma infecção com um pestivírus em animais, e, ensaio diagnóstico | |
| MX2021008035A (es) | Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña. | |
| MX2021004859A (es) | Vacuna de ibv h52 con proteina espicular heterologa. | |
| MX2024008983A (es) | Polipeptidos quimericos | |
| CO2025005381A2 (es) | Construcciones t car que comprenden un nuevo aglutinante cd19 combinado con il18 y métodos para usar el mismo |